U.S. stock futures turned lower Friday morning following President Trump's announcement nominating former Fed Governor Kevin Warsh to chair the Federal Reserve, replacing Jerome Powell. The move injects fresh uncertainty into monetary policy outlook.
Brookfield Business Partners reported a robust 2025, generating over $2 billion from asset sales, reducing debt, and making strategic acquisitions. The firm is on the cusp of a major corporate restructuring into a single listed entity, aiming to boost liquidity and investor appeal in a shifting global landscape.
Despite a prolonged freight recession, ArcBest reports resilient fourth-quarter performance, driven by strategic cost controls, AI integration, and growth in managed logistics solutions, while outlining a cautious outlook for 2026.
SanDisk's stock surged after the data storage giant issued a blockbuster third-quarter outlook, far exceeding Wall Street expectations. The company credited soaring demand from artificial intelligence applications and announced a major extension to a key supply agreement, highlighting the intense competition for memory chips in the AI era.
The Rafah border crossing between Gaza and Egypt is set to partially reopen Sunday, marking a fragile step in the U.S.-brokered ceasefire. While offering a lifeline for medical evacuees and displaced families, the operation will be tightly controlled by Israeli, Egyptian, and EU officials, with significant restrictions on the movement of people and goods.
Apple's first-quarter revenue surged 16% to $143.8 billion, powered by what CEO Tim Cook called "staggering" demand for the iPhone 17, which generated over $85 billion in sales and fueled explosive growth in China.
Reports suggest Elon Musk is exploring a merger between Tesla and SpaceX as the EV maker pivots to AI, while Chinese automakers gain record European market share and regulatory battles intensify.
BrightSpire Capital, Inc. (BRSP) finds itself predominantly in the hands of institutional investors, a vote of confidence that brings both stability and potential volatility. As major funds like Vanguard and BlackRock hold significant shares, the stock's trajectory is closely tied to their moves.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
A dramatic rally in gold and silver prices came to an abrupt halt on Friday, with futures tumbling sharply amid a broader market sell-off and warnings of unsustainable volatility.
Selective Insurance Group reported robust profitability and investment returns for 2025, driven by disciplined underwriting actions. While celebrating an 18% book value growth, management detailed significant reserve strengthening in commercial auto and outlined a confident outlook for 2026, the year of its centennial.
Minerals 260 (ASX:MI6) has significantly upgraded the resource estimate at its flagship Bullabulling gold project to 4.5 million ounces, sparking renewed investor interest. Despite recent share price volatility, the long-term outlook appears buoyed by upcoming study milestones and a substantial intrinsic value gap, raising questions about whether the market is undervaluing its potential.
Chemed Corporation (NYSE: CHE) has seen its share price soften recently, reigniting investor debate over whether the healthcare services provider is now undervalued. With the stock trading around $430, a significant gap exists against some fair value estimates, even as operational challenges in its VITAS and Roto-Rooter segments loom.
United Natural Foods, Inc. launches a landmark grant program across all 50 U.S. states and Canada to celebrate its 50th year, even as its stock performance presents a mixed picture for value-focused investors.
Discount retailer Five Below is under investigation by law firm Johnson Fistel following declining sales, lowered guidance, and the sudden departure of its CEO. The legal scrutiny comes as the stock shows sharp volatility—up nearly 96% over the past year but down year-to-date—raising questions about its valuation and growth narrative.
Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.
Bank of America has increased its price target for industrial packaging firm Greif (GEF) by $1 to $75, while reiterating a Neutral rating. The adjustment follows the bank's broader reassessment of the packaging sector after recent quarterly earnings calls.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
UBS initiates coverage on Rithm Capital with a Buy rating and a $16 price target, highlighting the REIT's aggressive acquisition strategy—including the purchases of Paramount Group and Crestline—as a key driver for expanding its asset management footprint and unlocking shareholder value.
